Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy
Chinese Chemical Letters · 2026-11 · 113604
DOI: 10.1016/j.cclet.2026.113604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Chemical Letters, 2026-11. Verfasst von Tao Liu und 9 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Liu, T., Liu, G., Fang, C., Zhong, H., Dong, Y., Shao, Y., Song, S., Wu, J., Guo, S., & Shang, Z. (2026). Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy. Chinese Chemical Letters, 113604. https://doi.org/10.1016/j.cclet.2026.113604
Vancouver
Liu T, Liu G, Fang C, Zhong H, Dong Y, Shao Y, et al. Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy. Chinese Chemical Letters. 2026:113604. doi:10.1016/j.cclet.2026.113604
BibTeX
@article{Liu2026,
author = {Liu, Tao and Liu, Guohua and Fang, Cheng and Zhong, Haiping and Dong, Yanliang and Shao, Yi and Song, Shengju and Wu, Jun and Guo, Shutao and Shang, Zhiqun},
title = {Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy},
journal = {Chinese Chemical Letters},
year = {2026},
pages = {113604},
doi = {10.1016/j.cclet.2026.113604}
}
EUVIMED